Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line

Biomarker Research

Table 1 Statins can inhibit cell cycle progression and mevalonate can reverse the inhibitory effect

Statins Reduce YT-INDY Cell cycle progression
	Cell cycle phases
	G0/G1 (%)	G2/M (%)	S (%)
Control	36.1 ± 0.44^a	10.6 ± 0.53	53.3 ± 0.69
50 µM Simvastatin	49.1 ± 0.30 ^b	13.1 ± 1.01	37.8 ± 0.97
50 µM Simvastatin + Mevalonate	39.9 ± 0.36	13.8 ± 0.48	46.3 ± 0.66
50 µM Simvastatin + GGPP	47.9 ± 0.64	13.6 ± 0.32	38.5 ± 0.87
Control	29.3 ± 0.80	6.8 ± 0.21	63.9 ± 0.97
50 µM Fluvastatin	41.7 ± 2.02	21.4 ± 1.67	36.9 ± 0.77
50 µM Fluvastatin + Mevalonate	33.9 ± 1.60	6.7 ± 0.15	59.4 ± 1.62
50 µM Fluvastatin + GGPP	42.1 ± 2.08	10.4 ± 0.43	47.5 ± 1.24
Control	27.9 ± 1.00	5.6 ± 1.03	66.5 ± 0.15
50 µM Lovastatin	50.4 ± 0.62	10.7 ± 0.84	38.9 ± 0.28
50 µM Lovastatin + Mevalonate	30.2 ± 0.15	3.7 ± 0.32	66.1 ± 0.47
50 µM Lovastatin + GGPP	39.6 ± 0.90	8.2 ± 0.72	52.2 ± 0.92

^aValues represent the means ± S.E.M. from three separate experiments.
^bBolded values represent statistical significance at least p < 0.05 compared to control values.
YT-INDY, incubated with or without statin drug or statin solvent, and with or without mevalonate or geranylgeranyl pyrophosphate (GGPP), were subjected to cell cycle analysis by flow cytometry.

ISSN: 2050-7771